DeepCRE: Revolutionizing Drug R&D with Cutting-Edge Computational Models

The fields of pharmaceutical development and therapeutic application both face substantial challenges. The therapeutic domain calls for more treatment alternatives, while numerous promising pre-clinical drugs have failed in clinical trials. One of the reasons is the inadequacy of Cross-drug Response Evaluation (CRE) during the late stage of drug development. Although in-silico CRE models offer a solution to this problem, existing methodologies are either limited to early development stages or lack the capacity for a comprehensive CRE analysis. Herein, we introduce a novel computational model named DeepCRE and present the potential of DeepCRE in advancing therapeutic discovery and development. DeepCRE outperforms the existing best models by achieving an average performance improvement of 17.7\% in patient-level CRE and a 5-fold increase in indication-level CRE. Furthermore, DeepCRE has identified six drug candidates that show significantly greater effectiveness than a comparator set of two approved drugs in 5/8 colorectal cancer (CRC) organoids. This highlights DeepCRE's ability to identify a collection of drug candidates with superior therapeutic effects, underscoring its potential to revolutionize the field of therapeutic development.

Empowering AI drug discovery with explicit and implicit knowledge

Motivation: Recently, research on independently utilizing either explicit knowledge from knowledge graphs or implicit knowledge from biomedical literature for AI drug discovery has been growing rapidly. These approaches have greatly improved the prediction accuracy of AI models on multiple downstream tasks. However, integrating explicit and implicit knowledge independently hinders their understanding of molecules. Results: We propose DeepEIK, a unified deep learning framework that incorporates both explicit and implicit knowledge for AI drug discovery. We adopt feature fusion to process the multi-modal inputs, and leverage the attention mechanism to denoise the text information. Experiments show that DeepEIK significantly outperforms state-of-the-art methods on crucial tasks in AI drug discovery including drug-target interaction prediction, drug property prediction and protein-protein interaction prediction. Further studies show that benefiting from explicit and implicit knowledge, our framework achieves a deeper understanding of molecules and shows promising potential in facilitating drug discovery applications.